STOK
NASDAQStoke Therapeutics Inc.
Price$29.01-0.23 (-0.79%)
01:30 PM07:45 PM
News · 26 weeks81-25%
2026-01-182026-07-12
Mix3390d
- Insider14(42%)
- Other9(27%)
- SEC Filings6(18%)
- Earnings2(6%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Harrison Seth Loring4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Mccauley Thomas4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mccauley Thomas3 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- PRStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on July 15, 2026, it granted stock options to purchase shares of common stock to Thomas McCauley, the Company’s newly-appointed Chief Scientific Officer, and seven other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted Mr. McCauley stock options to purchase 225
- ANALYSTGoldman initiated coverage on Stoke Therapeutics with a new price targetGoldman initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $44.00
- PRStoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer–Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases– Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Thomas McCauley, Ph.D., has been appointed Chief Scientific Officer. Dr. McCauley joins Stoke with more than 25 years of experience leading high-performing R
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry sold $236,068 worth of shares (7,228 units at $32.66) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 27,598 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SECSEC Form 8-K filed by Stoke Therapeutics Inc.8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
- PRStoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027 to complete the rolling U.S. NDA submission in the second half of 2027— Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen. Stoke plans to initiate a rolli
- INSIDERGENERAL COUNSEL & CORP SEC Allan Jonathan sold $43,637 worth of shares (1,457 units at $29.95) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 18,086 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- PRStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on June 15, 2026, it granted stock options to purchase an aggregate of 103,020 shares of common stock to nine new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $30.00 per share, which is equal to the closing price of Sto
- INSIDERSEC Form 4 filed by Director Tzianabos Arthur4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith Julie4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Levin Arthur A4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Krainer Adrian R.4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Kaye Edward M. Md4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Harrison Seth Loring4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Burstein Jennifer4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SECSEC Form 8-K filed by Stoke Therapeutics Inc.8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry sold $54,891 worth of shares (1,795 units at $30.58) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 34,826 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- PRStoke Therapeutics to Present at Upcoming Investor Conferences in JuneStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 9:20 a.m. ET Location: New York, NY Goldman Sachs 47th Annual Global Healthcare Conference 2026 Date: Monday, June 8, 2026 Time: 10:40 a
- PRStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on May 15, 2026, it granted stock options to purchase an aggregate of 106,200 shares of common stock to eight new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $30.08 per share, which is equal to the closing price of Sto
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
STOK FAQ
7 questionsWhat does Stoke Therapeutics Inc. do?
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera...Where does STOK stock trade?
Stoke Therapeutics Inc. (STOK) is listed on NASDAQ.What sector and industry is STOK in?
Stoke Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Stoke Therapeutics Inc. go public?
Stoke Therapeutics Inc. (STOK) completed its IPO in 2019.What are analysts saying about STOK?
Stoke Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy with a $4400.00 price target on 2026-07-13. Recent price targets range from $1800.00 to $4400.00.What companies are similar to STOK?
Notable peers in the same industry include GTHX (G1 Therapeutics Inc.), GRTX (Galera Therapeutics Inc.), MCRB (Seres Therapeutics Inc.). Compare STOK side-by-side with any of them on Quantisnow.How can I track STOK on Quantisnow?
Quantisnow aggregates Stoke Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STOK to receive live email and push alerts on every new disclosure.